Mira Pharmaceuticals Inc. has announced positive results from a proof-of-concept validation study of its oral drug candidate, Ketamir-2, aimed at treating post-traumatic stress disorder (PTSD). The study, conducted on rats using the Single Prolonged Stress model, showed that Ketamir-2 restored normalized behavior in stressed animals. Animals were exposed to a predator stressor, which induced PTSD-like symptoms, and were then treated with Ketamir-2. The treatment was associated with a reversal of PTSD-like behaviors to levels observed in non-stressed animals. Ketamir-2 targets the NMDA receptor with low affinity and has demonstrated superior efficacy in preclinical studies compared to ketamine, pregabalin, and gabapentin. It is not considered a controlled substance by the U.S. Drug Enforcement Administration. The company is conducting a larger follow-on PTSD study and a Phase 1 clinical trial for neuropathic pain, where Ketamir-2 has shown a favorable safety profile.